Head-to-head · the audited number vs the open file
NexLife vs Orderly: how to compare a known against an unknown
Our rules almost forbid this page. One side has the field's only closed audit — 24 published prices confirmed at live checkouts on August 14, 2026. The other is 2026's breakout search name with a file that is honestly, deliberately open: claims tracked, nothing verified. So instead of faking a symmetric review, this page does the more useful thing — it shows how to compare a verified figure against an unverified one, using Orderly as the live case.
The two records, stated plainly
NexLife's record: $169 month-to-month falling to $139 on twelve months for tirzepatide ($139→$119 semaglutide), dose-proof by policy, care bundled, 30-day exit — every figure stamped, with its own open items (pharmacy identity, state list) disclosed rather than hidden. Orderly's record: surging attention, published claims logged in the dataset, and a checkout no one here has walked. Attention is a fact about the market; it is not a fact about the price.
Pricing the difference between verified and claimed
Suppose Orderly's true all-in turned out $20 a month cheaper. Would unverified-$20 beat audited-certainty? Frame it as what the $240 annual gap buys: on the audited side, a contractual dose-proof rate, known exit terms, and a number that has already survived checkout; on the claimed side, the possibilities every unaudited program carries — a starter-dose sticker, a renewal ladder, a fee outside the headline. Verification isn't a vibe; it's the deletion of those failure modes, and it is worth real money. That is the entire logic of this site's iron rule: an audited figure outranks a lower unaudited one until the audit happens.
The five questions that would close Orderly's file
Anyone can run our audit before we do. Get, in writing: the all-in monthly price at maintenance dose, not the door; whether that price moves with dose steps; the name and license of the dispensing pharmacy; renewal and cancellation terms, verbatim; and the state list. Five confident, documented answers convert an open file into a comparable one — and if the audited math then favors Orderly, this page's verdict flips, in public, in the corrections log.
The verdict, as a rule
Today: the known beats the unknown — $139, stamped. Not because Orderly is bad; because Orderly is unproven, and money spent monthly deserves proof. The moment its checkout is walked, this comparison gets rewritten from evidence. Compounded product on both sides carries no FDA review; fit is a clinician's call.
NexLife — the audited benchmark ↗ Orderly — run the five questions ↗
Both are partner links with sponsored tags; the rule above predates both. How the money works.
Is Orderly Meds legit?
Its file is open: real search momentum, published claims, no independently walked checkout. Legitimacy questions are exactly what the five written questions above resolve — pharmacy name, maintenance-dose price, renewal terms, cancellation, states.
Is Orderly cheaper than NexLife?
Unknown — no Orderly figure here is audited. The audited benchmark is $139/month all-in; a lower unverified claim doesn't outrank it under our rules.
When will Orderly be audited?
It sits first among breakout names in the audit queue; the file and this verdict update publicly the day the checkout is walked.
More head-to-heads: NexLife vs Hims · NexLife vs Mochi · NexLife vs Ro · Mochi vs Orderly